1004791-44-9

Upstream product

• 191655-29-5 (S)-(3-benzyloxy-2-t-butoxycarbonylaminopropoxy)acetic acid t-butyl ester 
• 348-61-8 1-bromo-3,4-difluorobenzene 
• 1004791-41-6 (3R,5S)-3-(3,4-difluorophenyl)-5-hydroxymethylmorpholine-4-carboxylic acid 9H-fluorene-9-ylmethyl ester 
• 1004791-42-7 (3R,5R)-3-(3,4-difluorophenyl)-5-(1-hydroxyethyl)morpholine 4-carboxylic acid 9H-fluoren-9-yl methyl ester 
• 1050392-21-6 {(S)-2-benzyloxymethyl-1-[2-(3,4-difluorophenyl)-2-oxoethoxymethyl]ethyl}carbamic acid t-butyl ester 
• 937400-45-8 [(3S,5R)-5-(3,4-difluorophenyl)morpholine-3-yl]methanol 
• 937400-29-8 (S)-3-benzyloxymethyl-5-oxomorpholine-4-carboxylic acid tert-butyl ester 
• 937400-28-7 (5S)-5-[(benzyloxy)methyl]morpholin-3-one 
• 79-37-8 oxalyl dichloride 
• 1004791-43-8 (3R,5R)-3-(3,4-difluorophenyl)-5-(1-hydroxyethyl)morpholine 

Relevant academic research and scientific papers

Prodrug of cinnamide compound

The present invention provides a most suitable prodrug of a cinnamide compound. The prodrug is represented by Formula (I) wherein Ra and Rb each denote a C1-6 alkyl group or the like; Xa denotes a methoxy group or a fluorine atom; Y denotes a phosphono group or the like; and A denotes a cyclic lactam derivative.

TWO CYCLIC OXOMORPHORIN DERIVATIVES

The present invention relates to a compound represented by formula (I): wherein R1 represents a C1-3 alkyl group, R2 represents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.